Dr Essie Low
(03) 9342 7539
(03) 9342 7572
Seeking participants with mild cognitive impairment or early Alzheimer's disease
ANAVEX – A clinical trial that aims to assess the safety and efficacy of a new drug for the treatment of early Alzheimer’s disease
The main aim of this study is to investigate the effectiveness of a new drug (ANAVEX 2-73) in treating early Alzheimer’s disease. Two clinical studies investigating use of ANAXVEX 2-73 in human subjects have been completed and have shown positive outcomes in cognition, such as memory, attention, speed of processing and reasoning and problem solving.
The current study extends on previous findings to further investigate the effect of this drug (including at varying dose levels) on cognitive and functional outcomes – the former being various aspects of thinking abilities and the latter being independence in completion of daily activities.
Recruitment status: Ongoing
Who can take part
To participate in this study, the potential participant must:
- Be between 60 and 85 years of age
- Have a diagnosis of either Mild Cognitive Impairment due to Alzheimer's or mild Alzheimer's disease
- Have a study partner who is able to spend at least 10 hours weekly with you
- Be on stable medications for at least 3 months
- Be able to attend visits at the Royal Melbourne Hospital – city campus
What is involved for you
Participation will involve being on the investigational drug for 48 weeks and attending 6 scheduled clinic visits and 1 scheduled telephone call. Procedures that will occur during clinic visits and over the duration of the study include:
- Blood and urine tests
- Vital signs and ECGs
- Physical and neurological examination
- Completion of questionnaires
- Assessment of thinking abilities
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
For more information
Quote reference number
2016.097Natalie McKelvie
(03) 9342 7572